Pasithea Therapeutics Corp.

KTTA Healthcare Biotechnology

In the quarter to June 2026, EPS grew 75.8% and free cash flow fell 21.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.42 0.01 +2.44%
Market cap
$13.7M
P/E
0.0×
Fwd P/E
0.0×
Dividend yield
—
F-score
n/a
Altman Z
2.97
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
26.25 35.40 11.35 4.02
Net Debt/EBITDA
8.24 10.70 5.47 1.44
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.15) (0.20) (0.77) (0.39)
Book value per Share
1.55 2.25 7.85 1.64
Free Cash Flow
(4.71) (4.79) (5.39) (2.89)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates